Last reviewed · How we verify

Aspirin and clopidogrel/Ticagrelor

Beijing Neurosurgical Institute · FDA-approved active Small molecule

Aspirin and clopidogrel/Ticagrelor is a Dual antiplatelet agent Small molecule drug developed by Beijing Neurosurgical Institute. It is currently FDA-approved for Acute coronary syndrome, Secondary prevention of cardiovascular events post-myocardial infarction, Stroke prevention.

This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways.

This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-myocardial infarction, Stroke prevention.

At a glance

Generic nameAspirin and clopidogrel/Ticagrelor
SponsorBeijing Neurosurgical Institute
Drug classDual antiplatelet agent
TargetCOX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel and ticagrelor are P2Y12 receptor antagonists that block adenosine diphosphate (ADP)-mediated platelet aggregation. Together, this dual antiplatelet therapy provides synergistic inhibition of platelet function to prevent thrombotic events.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aspirin and clopidogrel/Ticagrelor

What is Aspirin and clopidogrel/Ticagrelor?

Aspirin and clopidogrel/Ticagrelor is a Dual antiplatelet agent drug developed by Beijing Neurosurgical Institute, indicated for Acute coronary syndrome, Secondary prevention of cardiovascular events post-myocardial infarction, Stroke prevention.

How does Aspirin and clopidogrel/Ticagrelor work?

This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways.

What is Aspirin and clopidogrel/Ticagrelor used for?

Aspirin and clopidogrel/Ticagrelor is indicated for Acute coronary syndrome, Secondary prevention of cardiovascular events post-myocardial infarction, Stroke prevention.

Who makes Aspirin and clopidogrel/Ticagrelor?

Aspirin and clopidogrel/Ticagrelor is developed and marketed by Beijing Neurosurgical Institute (see full Beijing Neurosurgical Institute pipeline at /company/beijing-neurosurgical-institute).

What drug class is Aspirin and clopidogrel/Ticagrelor in?

Aspirin and clopidogrel/Ticagrelor belongs to the Dual antiplatelet agent class. See all Dual antiplatelet agent drugs at /class/dual-antiplatelet-agent.

What development phase is Aspirin and clopidogrel/Ticagrelor in?

Aspirin and clopidogrel/Ticagrelor is FDA-approved (marketed).

What are the side effects of Aspirin and clopidogrel/Ticagrelor?

Common side effects of Aspirin and clopidogrel/Ticagrelor include Bleeding, Gastrointestinal bleeding, Dyspepsia, Bruising, Headache.

What does Aspirin and clopidogrel/Ticagrelor target?

Aspirin and clopidogrel/Ticagrelor targets COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor) and is a Dual antiplatelet agent.

Related